**Mycobacterium abscessus** disease in lung transplant recipients: Diagnosis and management

Satish Chandrashekarana, Patricio Escalanteb,d, Cassie C. Kennedyc,e,*

a Division of Pulmonary, Critical Care and Sleep Medicine, Lung Transplantation Program, University of Florida, Gainesville, FL, United States
b Mycobacterial and Bronchiectasis Clinic, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, United States
c Division of Pulmonary and Critical Care Medicine, Department of Medicine, Rochester, MN, United States
d Mayo Clinic Center for Tuberculosis, Mayo Clinic, Rochester, MN, United States
e William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, United States

**A R T I C L E   I N F O**

**Keywords:**
Mycobacterial abscessus complex  
Lung transplant  
Lung infection

**A B S T R A C T**

*Mycobacterium abscessus* complex (MAbsC) disease in lung transplant recipients is increasingly being recognized as an important cause of graft function decline and suboptimal outcomes. Lung transplant recipients appear to be at the highest risk of MAbSC among solid organ transplant recipients, as they have more intense immunosuppression, and the organisms preferentially inhabit the lungs. MAbSC is the most resistant species of rapidly growing mycobacteria and difficult to treat, causing considerable mortality and morbidity in immunocompetent and immunosuppressed patients. Herein we describe the risk factors, epidemiology, clinical features, diagnostics, and treatment strategies of MAbSC in lung transplant candidates and recipients.

1. Introduction

Mycobacterial infections remain a significant cause of morbidity and mortality in lung transplant recipients [1]. Therefore, careful scrutiny of potential transplant recipients is necessary. “Chronic infection with highly virulent and/or resistant microbes” is considered an absolute contraindication to lung transplant, while colonization with the same is considered a relative contraindication [2]. One such infection that remains controversial is *Mycobacterium abscessus* complex (MAbsC) pulmonary infections. This group of non-tuberculous mycobacteria (NTM) infections includes *M. abscessus subsp. abscessus* (MAA), *M. abscessus subsp. bolletii* (MAB) and *M. abscessus subsp. massiliense* (MAM) [3,4].

Immunocompetent individuals without structural lung disease usually do not develop NTM pulmonary disease [5,6]. However, patients with immunosuppressive conditions – such as solid organ transplant recipients – are at the highest risk for pulmonary and disseminated NTM disease. NTM that frequently cause pulmonary disease in lung transplant recipients include *Mycobacterium avium* complex (MAC) followed by *MAbsC* [7–9]. In addition, some experts consider that NTM disease is an under-recognized cause of graft dysfunction in lung transplant recipients [5,10].

MAbsC are part of the rapidly growing mycobacteria (RGM) associated with significant pathogenicity, and they account for 65–80% of RGM isolates in the United States [11,12]. MAA disease is increasingly recognized as the most virulent of the NTM infections [13]. MAA pulmonary disease is associated with severe infection and rapid decline in lung function when compared to other NTM pulmonary infections [9]. MAA is among the most antibiotic-resistant NTM species and, thus, most difficult to treat and cure, and unfortunately, it is associated with considerable morbidity and mortality in the lung transplant recipients [14].

2. Epidemiology

NTM are ubiquitously found in the environment, including in soil, dust, natural water sources and municipal water supplies [11]. NTM also colonize the skin, respiratory and gastrointestinal secretions in humans [15]. The number of NTM species recognized today has increased to more than 140 species [11,16,17]. Improved mycobacterial laboratory methodology using molecular laboratory techniques has resulted in identification that is more accurate and increased recognition of NTM lung disease [3,11]. MAbSC and other RGM colonize organic surfaces and produce growth in solid media within seven days [12,18]. RGM are able to survive in treated water sources like municipal tap water as they are resistant to many commonly used disinfectants including chlorine, glutaraldehyde, chloramine, ozone and organomercurials [12]. Human disease is mostly acquired from...
environmental exposure [11] However, patient-to-patient andomite-related transmission of MAbSC, including (MAM), have been reported, highlighting the ability of these organisms to cause outbreaks and to disseminate globally [19,20].

The exact incidence of MAbSC pulmonary disease in lung transplant recipients is not known as reporting of NTM infections is not mandatory, unlike TB. Incidence and prevalence of MAbSC disease appears to be increasing [12]. The increased prevalence could be related to an increase in the frequency of transplants, more potent immunosuppressive regimens, improved diagnostic procedures and increased vigilance and surveillance for these organisms [6,15,21]. Lung transplant recipients are at highest risk among the solid organ transplant recipients for NTM infections as the organisms preferentially inhabit the lungs and lung transplant recipients have more intense immunosuppression [21,22]. In one study, cumulative incidence for MAbSC disease was thought to be somewhere around 0.33% [5]. MAbSC disease in lung transplant recipients are more frequently reported as allograft infection (pleuroparenchymal disease) followed by skin, soft tissue and disseminated disease [5,22]. The majority of MAbSC disease in lung transplant recipients occurs in the first 8 months after transplantation. This might be due higher intensity immunosuppression used during this period [22]. MAbSC infections are reported more frequently from southern coastal states that include Florida and Texas which also appear to be the major endemic areas. [11,12,23].

3. Risk factors

The pathophysiology of NTM diseases in otherwise healthy subjects appears to be related to a number of factors including the pathogenicity of the NTM species, environmental exposures and complex host-genetic factors associated with ciliary function, immune function, connective tissue pathways, and the transmembrane conductance regulator (CFTR) [17,24]. Other risk factors associated with the development of NTM pulmonary disease in immunocompetent patients include structural lung disease and upper gastrointestinal tract diseases. Similar to other NTM infections, MAbSC lung disease is more common in patients with chronic obstructive pulmonary disease and emphysema, bronchiectasis, cystic fibrosis (CF), alpha-1 anti-trypsin deficiency, pneumoconiosis, sarcoidosis and pulmonary tuberculosis [5,11,14,23]. Moreover, there is very little information regarding the nature of the host immune response to MAbSC infections from animal models and human studies [25]. Reduced Th1 and Th2 cell immune responses associated with upregulated Th17 response have been reported in patients with MAbSC pulmonary disease compared to healthy controls [26]. In a small study of CF patients, an increased frequency of antigen-specific peripheral blood T cells expressing CD40L(+) but not IL-2(+) was found mostly in patients with MAbSC pulmonary disease [27]. This limited immune profiling information suggests that MAbSC infections are associated with alterations in some specific pathways of cell-mediated immunity that may contribute to disease progression. In addition, esophageal dysmotility and gastroesophageal reflux are considered important risk factors for the development of MAbSC lung disease [11,23]. Some experts believe that true colonization with MAbSC does not exist; patients who have minimal clinical features have minimal disease [14]. In pulmonary transplant recipients, the potential risk factors for the development of MAbSC disease include immunosuppression and the development of structural lung disease over time due to chronic lung allograft dysfunction [7,22].

Routine screening for NTM infection is recommended in all patients with CF due to the high prevalence of NTM pulmonary disease in this population [12]. Pre-transplant isolation of MAbSC in CF patients is a major risk factor for MAbSC-related cervical lymphadenitis, wound infection, and mediastinal abscess, which can progress to disseminated disease after organ transplantation (Table 1) [5,9,13,14,19,28,29,30]. The candidacy of CF patients who have history of MAbSC disease should be very carefully evaluated in experienced centers as some would consider isolation of MAbSC as a relative contraindication to lung transplantation [2,28].

4. Microbiology

RGM are acid-fast bacilli (AFB) and stain as gram-positive beaded rods on gram stain. Fluorochrome (auramine or auramine-rhodamine) is the preferred method of acid-fast staining. Broth and solid media are recommended for MAbSC culture. Rapid identification of MAbSC subspecies can be performed by molecular methods [12].

Table 1

A summary of reported cystic fibrosis/bronchiectasis patients with pre-transplant isolation of M. abscessus complex receiving bilateral lung transplants.

| Author          | Diagnosis | Age/sex | N Site | Recurrence (days post) | Site of recurrence | Outcome         | Cause of death               |
|-----------------|-----------|---------|-------|------------------------|--------------------|-----------------|------------------------------|
| Aitken et al.   | CF        | 22/M    | 1     | Sputum positive        | Lung               | Died            | Overwhelming M abscessus infection |
| Chernenko et al.| CF        | 29/M    | 2     | Lung                   | 1 month            | Died 2 months   | Sepsis from pseudomonas and aspergillus |
| Taylor et al.   | Bronchiectasis | 57/F | 1   | Lung                   | 5 months           | Died 14 months  | Sepsis from C diff colitis |
| Gilljam et al.  | CF        | 10/1, 28/F, 26/F | 3   | Lung                   | 19 months          | Died            | Disseminated M abscessus     |
| Zaidi et al.    | CF        | 17/M    | 1     | Lung                   | 50 days            | Died 87 days    | Alive                       |
| Qvist et al.    | CF        | 39/M    | 6     | Lung                   | 1 year             | Alive           | Alive                       |
|                 | CF        | 22/M    | 1     | Blood                 | Deep tissue infection | Died 19 days | ARDS |
| Lobo et al.     | CF        | 22/F    | 3     | Mediastinal abscess    | Lung               | Died            | NTM sepsis                  |
|                 | CF        | 32/M    | 2     | Empyema, sternal OM   | Alive              | Alive           | Alive                       |

All the patients had pre-transplant MAbSC disease. Most common listing diagnosis was CF. These patients had recurrence after transplantation. Most common site for recurrence was sternal, mediastinum and soft tissue infections. N = number of cases; CF = cystic fibrosis; F = female; M = male; OM = osteomyelitis; ARDS = adult respiratory distress syndrome; CLAD = chronic lung allograft dysfunction. BOS = bronchiolitis obliterans syndrome.
4.1. Erythromycin methylase gene (erm gene)

Macrolides bind to 50s ribosomal subunit and inhibit peptide synthesis. Erythromycin methylase (erm) genes prevent the binding of macrolides to ribosomes and diminish the inhibitory activity of these agents. The erm gene is the primary mechanism of innate and clinically significant macrolide resistance in M. abscessus [3]. When MAA or MAB isolates are exposed to macrolide, the erm gene activity is induced with subsequent in vivo macrolide resistance. This may not be apparent by the initial in vitro MIC of the organism for the macrolide. This might be one of the mechanisms for the discrepancy between in vitro susceptibility results and in vivo response. In order to unmask this inducible macrolide resistance, the NTM isolate should be incubated with a macrolide for up to 14 days to induce this erm gene. Standard incubation for 3 days used to determine minimal inhibitory concentration (MIC) is not enough to induce erm gene resistance. As a result, the isolate might falsely show in vitro susceptibility to macrolide if it is not incubated for 14 days [3,16,31]. DNA sequencing has demonstrated that MAM have a large deletion in erm gene, which is associated with a nonfunctional gene and macrolide susceptible phenotype for these isolates. On the other hand, MAA and MAB lack this deletion and the erm gene is functional causing macrolide resistance [3]. Hence, MAM is susceptible to macrolides and have better treatment outcomes at eradication compared to MAA where 80% of isolates are macrolide resistant and are very difficult to treat and eradicate [18,32,33] (Table 2).

Table 2
Mycobacterium abscessus subspecies and their macrolide resistance patterns.

| Name                        | erm gene functional | Resistance          |
|-----------------------------|---------------------|---------------------|
| M. abscessus subsp. abscessus (MAA) | Yes                 | Macrolide resistance |
| M. abscessus subsp. bolletii (MAB) | Yes                 | Macrolide resistance |
| M. abscessus subsp. massiliense (MAM) | No                  | Macrolide susceptible |

Reference [3].

5. Pretransplant screenings and management

The transplant community lacks consensus in how to treat MABsc infection in a potential lung transplant candidate. Some argue MABsc isolation prior to lung transplantation is a relative contraindication to lung transplantation [28]. However, this is controversial because local control and infection clearance is possible in recurrent cases [9,34]. Moreover, CF patients with pre-existing MABsc pulmonary disease have successfully achieved expected survival rates but they are at risk of developing difficult-to-treat soft-tissue infections [30]. MABsc infection is an absolute contraindication to lung transplantation in some transplant centers due to concerns for increased morbidity, mortality, and risk of person-to-person spread after transplantation. There is consensus that all lung transplant candidates with structural lung disease (e.g. bronchiectasis) and risk factors for NTM should be screened for mycobacteria and NTM disease. This will identify more patients with pre-transplant MABsc disease. Type of screening will be dependent on the severity of underlying lung disease. For patients on high-flow oxygen supplementation, bronchoalveolar lavage may not be feasible, hence sputum smear testing for AFB stain and mycobacteria cultures should be performed [8].

There are no standardized guidelines for diagnosis and management in the pre-transplant evaluation. In order to reduce transplant risks, experts recommend eradication of NTM infection should be attempted prior to lung transplantation, and all foreign bodies should be removed at the time of lung transplantation which include indwelling lines and even some suggest the removal of breast implants [28,30,34]. Patients should be adequately treated with multidrug regimens. Pre-transplant patients who have three sputum samples negative for AFB stain and mycobacteria cultures for more than one year are considered cleared and could be listed [9]. However, in the case series described by Lobo et al only 3 of the 13 CF patients with MABsc disease pre-transplant were able to clear the infection despite aggressive therapy (mean duration of multidrug treatment was 10 months), demonstrating the difficulty of clearing MABsc disease.

In situations where listing cannot be delayed, the multidrug regimen could be continued in the post-transplant phase for 6 weeks or more while the surveillance for MABsc isolation should continue with BAL, sputum and wound cultures [9]. This is particularly important since those lung transplant recipients are a high risk to develop MABsc wound infection, sternal abscess, skin, soft tissue and disseminated disease. [9,28,29]. Moreover, AFB stains and mycobacteria cultures should be obtained from the donor bronchial washings, bronchoalveolar lavage if feasible and intraoperative samplings should be encouraged in individuals at risk.

During lung transplantation surgery, removal of the diseased lungs probably serves as a means of decreasing “disease burden”. The surgery in addition to aggressive antimicrobial treatment can help achieve disease eradication [9]. Moreover, the native lung in single lung transplant recipients could act as a potential source of infection that could infect the allograft [8]. Hence, patients with a history of pre-transplantation MABsc disease should be considered for bilateral lung transplantation to decrease disease burden and prevent reinfection of the graft.

Following transplantation, repeated surface cleaning of clinic and equipment and isolation procedures should occur between patients to avoid transmission of MABsc. Transplant centers should also consider placing patients with MABsc disease in negative pressure rooms and contact isolation during clinic visits as patient-to-patient and fomite-related transmission of MABsc, including (MAM) have been reported [19,20].

6. Immunosuppression in lung transplantation

It has to be recognized that the immunosuppression required following lung transplantation is much higher than that of any other solid organ transplantation [35]. This might relate to endogenous factors (large number of donor-derived dendritic cells capable of stimulating T cells) and exposure to environmental antigens which might be responsible for triggering frequent rejections [35]. Immunosuppression is used to reduce both acute and chronic rejection in lung transplant recipients. This higher level of immunosuppression contributes to higher incidence of opportunistic infections, including MABsc, in lung transplant recipients when compared to other solid organ transplantation.

7. Clinical features of M Abc absolute disease in lung transplant recipients

Disease in immunosuppressed lung transplant recipients ranges from pulmonary disease, lymph node involvement, localized cutaneous lesions, thoracotomy wound infection, sternal osteomyelitis, empyema to disseminated infections [6,7,21]. Most common initial presentation is pulmonary disease followed by cutaneous lesions [5,21,36].

7.1. Pulmonary disease

Patients with pulmonary disease could present with cough, fever, chills, chest pain, dyspnea, expectoration, and/or hemoptysis. Others may present with non-specific symptoms like fatigue, malaise and weight loss. Some patients are asymptomatic. Nearly half of the patients present with decline in lung function testing [5,12]. Empyema has also been described in some patients with MABsc infection after lung transplantation [37].
7.2. Skin and soft tissue disease

Cutaneous disease due to \textit{M. abscessus} could be from (1) surgical wound infection or (2) may be the initial presentation of disseminated disease [7,11,21]. Therefore, skin lesions have to be followed very closely [21]. Lesions have been described in upper or lower extremities, buttocks, breast and very rarely in multiple sites. Cutaneous lesions could occur before or after the allograft infection [5]. Lesions typically present as painful erythematous or violaceous nodules that may form abscesses. Some of these abscesses may open up to form ulcers [5]. A skin biopsy or aspirate for histopathologic examination is required to make a definitive diagnosis.

\textit{M. abscessus} is the most common NTM that causes surgical site infection in solid organ transplant recipients [22]. This is a very challenging complication to treat. Interestingly this has been seen more commonly in cystic fibrosis patients who were colonized with \textit{M. abscessus} prior to transplantation [9,13,29,30].

Disseminated disease presents as multiple draining cutaneous nodules or abscesses. There is no obvious portal of entry. Patients can also present with chronic cervical lymphadenopathy. The organism can be isolated in blood culture, tissue biopsy or aspirated material [12] (Fig. 1 and Fig. 2).

8. Radiological findings

The majority of patients present with pulmonary nodules, fibrocavitary disease, nodular bronchiectasis, or combination of these features. Common findings in chest high-resolution computed tomography (HRCT) include multifocal bronchiectasis with multiple small nodules and/or cavitary lesions [5,7]. Other findings in chest radiograph (CXR) and chest HRCT include focal consolidation, patchy multinodular opacities, as well as reticulonodular, interstitial and alveolar infiltrates with upper lobe predominance [12]. The pulmonary nodules are visualized on CXR in only 50% of the cases. Hence a HRCT of the chest should be performed if there is a high index of suspicion [5] (Fig. 3).

9. Diagnosis

The diagnosis of NTM lung disease should include presence of compatible symptoms, microbiological and radiological evidence as recommended by the ATS and IDSA guidelines for the diagnosis and treatment of NTM (Table 3) [11]. All three criteria must be met before the diagnosis of NTM lung disease is made. The evaluation of all patients suspected of NTM lung disease should include three or more sputum specimens obtained early in the morning and on three separate days for AFB analysis along with a CXR or chest HRCT (if no cavitation present on CXR) and exclusion of other pulmonary disorders like TB or malignancy. When performing expectorated sputum samples, patients should not drink or rinse their mouth with tap water prior to collection to minimize the risk of environmental contamination. Sputum can be induced with hypertonic saline nebulization if patient is unable to produce sputum. If unable to obtain sputum, bronchoalveolar lavage (BAL) with or without biopsy can be performed. [11,12]

As NTM are ubiquitous organisms, contamination of the specimens can occur during collection, transport and processing of the sample. Hence, a single positive expectorated culture is not adequate to make a definitive diagnosis of NTM lung disease. On the other hand, specimens obtained from bronchoalveolar lavage have less likelihood of environmental contamination; hence, a single positive culture obtained from BAL is considered adequate for microbiological diagnosis [11,12]. In lung transplant recipients diagnosis is established by bronchoalveolar lavage (BAL) in the majority and rarely by biopsy [5].

Fig. 1. Skin lesions, right lower extremity in a patient with disseminated \textit{M. abscessus} subsp. bolletii (MAB).

Fig. 2. Ziehl-Neelsen stain (acid fast stain) of the biopsy reveals numerous rod shaped acid fast bacilli (arrows, 400X).
Diagnostic criteria for NTM pulmonary disease as set forth by the 2007 ATS/IDSA guidelines (Table 3). All three criteria have to satisfy for diagnosis of NTM lung disease [11].

The presence of NTM in one bronchoalveolar lavage sample or two separate sputum samples in conjunction with compatible radiographic or CT imaging and clinical symptoms satisfies the ATS diagnostic criteria and constitutes NTM disease [11]. Moreover, approximately 20% of patients with $\text{MabsC}$ infection will also develop infection or disease due to $\text{M. avium}$ complex. [14]. Importantly, one has to be very careful in extrapolating the ATS/IDSA criteria to immunosuppressed lung transplant recipients, as these criteria have not been validated in lung transplant recipients [38].

### Table 3

ATS/IDSA diagnostic criteria for NTM pulmonary disease.

| Consistent clinical features along with | Radiological findings compatible with NTM along with | One of the following microbiological findings: |
|---------------------------------------|--------------------------------------------------|-----------------------------------------------|
| a) Two or more positive sputum cultures from different samples | b) One positive culture from bronchoalveolar lavage | c) Positive culture from lung biopsy or biopsy with mycobacterial features |

#### 10. Treatment

Once the diagnosis of $\text{MabsC}$ pulmonary disease is established, the next step would be to decide if the patient’s clinical condition warrants treatment and what antimicrobials to treat the patient with. Treatment decisions are made on a case-by-case basis and this would take into consideration the presence of other co-morbid conditions and the presence of other organ dysfunction. One has to decide if the treatment goal is curative, chronic suppressive therapy or palliative therapy [39]. Other considerations include the risks and benefits of therapy, the tolerability of treatment, the toxicities associated with the multi-drug regimen (Table 4). Drug interactions, especially with immunosuppressive medications should also be taken into consideration (See Table 5). If the patient is symptomatic and there are signs of clinical progression or a decline in graft function one should elect to treat. If possible the intensity of immunosuppression should be decreased. This might be difficult in the first year after transplantation. Coexisting viral infections like CMV infections should be treated [6]. In fact, some have suggested that the development of disease after lung transplantation could be an indicator for excessive immunosuppression since the great majority of the patients who die after $\text{MabsC}$ disease, succumb to other causes [8]. In patients with pre-transplant $\text{MabsC}$ disease, aggressive induction therapy with antithymocyte globulin should be avoided and post-transplant calcineurin target trough levels should be lowered if feasible. However, lowering immunosuppression to attempt to improve immune function to facilitate the control of infection should be balanced against the risk of organ rejection [34]. Every attempt should be to optimize nutritional status of these patients. In patients with impaired quantitative IgG levels, gamma globulin supplementation could be considered [29]. Along these lines, effective treatment for comorbid risk factors for NTM disease, including treatment for GERD and dysphagia can result in improvement of their $\text{MabsC}$ lung disease [11]. Patients with co-existing bronchiectasis should also receive optimal chest physiotherapy, including the use of bronchodilators, hypertonic saline nebulizations and the use of flutter valve, postural drainage, and/or high-frequency chest wall oscillation (i.e. Vest) therapy [40–42].

Antimicrobial treatment of $\text{MabsC}$ is very demanding and
Table 5

Drug interactions between antimicrobials used to treat M abscessus complex infections and immunosuppressive agents.

| Antibiotic          | Cyclosporine                                      | Tacrolimus                                      | Sirolimus                                      |
|---------------------|---------------------------------------------------|-------------------------------------------------|------------------------------------------------|
| Azithromycin        | Weak inhibition of CYP450 (weaker than Clarithromycin) leading to increase of cyclosporine levels | Weak inhibition of CYP450 leading to increase of tacrolimus levels | No known interaction                           |
| Aminoglycosides     | Increased risk of nephrotoxicity                  | Increased risk of nephrotoxicity                | No known interaction                           |
| Clarithromycin      | Inhibition of CYP450 leading to increase of cyclosporine levels | Inhibition of CYP450 leading to increase of tacrolimus levels | Inhibition of CYP450 leading to increase of sirolimus levels |
| Fluoroquinolones    | Weak inhibition of CYP450 leading to increase of cyclosporine levels | Weak inhibition of CYP450 leading to increase of tacrolimus levels | No interaction                                  |

Reference [15].

Table 6

Antimicrobial dosage examples and route of administration.

| Antibiotic      | Route            | Dose and frequency |
|-----------------|------------------|--------------------|
| Amikacin        | Intravenous      | 10–15 mg/kg daily, target peak serum levels |
| Clarithromycin  | Oral             | 500 mg twice daily |
| Azithromycin    | Oral             | 250–500 mg once daily |
| Cefoxitin       | Intravenous      | 200 mg/kg or 2 to 4 g twice or three times daily with a maximum of 12 g/daily |
| Imipenem        | Intravenous      | 500 mg to 1 g two to four times daily |
| Tigecycline     | Intravenous      | 25–50 mg daily |
| Linezolid       | Oral             | 600 mg twice daily |
| Claroizaminne   | Oral             | 100 mg daily |

Table 7

Maintenance immunosuppression examples in lung transplantation.

|                          | 0–12 months post lung transplantation | 12–24 months post lung transplantation | > 24 months post lung transplantation | Adverse effects to monitor                                      |
|--------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------------------------------|
| Calcineurin inhibitor    | 12 h trough level                      | 12 h trough level                      | 12 h trough level                      | Nephrototoxicity, hypertension, hypercholesterolemia, hyperkalemia, hypogammaglobulinemia, neurotoxicity (tremor, headache, PRES), thrombotic microangiopathy |
| Tacrolimus               | 10–14                                 | 8–12                                  | 6–12                                  | Leukopenia, thrombocytopenia, anemia, hepatotoxicity, pancreatitis |
| Cyclosporine (Neoral)    | 250–350 mg/ml                         | 200–300 mg/ml                         | 100–200 mg/ml                         | Leukopenia, G1 intolerance                                      |
| Azathioprine or          | 100–150 mg PO qd                      |                                        |                                        | G2 intolerance                                                |
| Mycophenolate mofetil    | 1000 mg PO bid                        |                                        |                                        |                                                                 |
| Myfortic plus            | 720 mg PO bid                         |                                        |                                        |                                                                 |
| Sirolimus*               | 10–15 mg/ml                           | 10–15 mg/ml                           | 5–8 ng/ml                             | Hyperglycemia, diabetes mellitus, weight gain, hypertension, hyperlipidemia, osteoporosis, cataracts |

* Note. Early post-transplant use of sirolimus is contraindicated due to reported anastomotic dehiscence.

important to know if the MAbC isolate has an active or inducible erm gene. The ability of the mycobacterial laboratory to provide subspecies level identification and presence or absence of an inducible erm gene will help the treatment plan immensely [16]. It is much more difficult to treat MAA and MAB than to treat MAM. The absence of inducible resistance to macrolides makes MAM more susceptible to these key antimicrobials in the antibiotic regimens [18,33]. Moreover, clarithromycin induction of the erm gene is greater than with the use of azithromycin, which explains a higher induction of macrolide resistance with clarithromycin than with azithromycin in MAA but not in MAM [44]. Hence, azithromycin might be more effective against MAA than clarithromycin whereas both macrolides might be equally effective against MAM. In the United States, there is more lung disease caused by MAA than MAB [31]. Many centers use azithromycin as a drug to prevent or slow obstructive CLAD (chronic lung allograft dysfunction), and thus, macrolide susceptibility and erm gene phenotypic testing should be obtained if information of MAbC subspecies is not readily available. Moreover, Azithromycin is a less potent cytochrome P 450 (CYP450) inhibitor than clarithromycin, which is an important consideration in order to design an antimicrobial regimen with less likelihood to interact with other patient’s drugs [6].

10.1. Treatment of pulmonary disease

The eventual goal of treatment of MAbC lung disease as in other NTM lung diseases is symptomatic improvement, resolution of radiologic findings, improvement in graft function, and achievement of 12 months of negative sputum cultures while on therapy [11,12].
Monotherapy with macrolides is not recommended because of the risk of emergence of macrolide resistance [15]. The antimicrobial agents with the best in vitro activity against \textit{MAbsC} include amikacin, clarithromycin, tigecycline and cefoxitin. Half of \textit{MAbsC} isolates will demonstrate at least intermediate susceptibility to linezolid and imipenem. [12,45].

The ATS/IDSA guidelines recommend combination of intravenous amikacin plus cefoxitin or imipenem and oral macrolide for at least 2–4 months [11]. One small series of 41 non-transplant patients with \textit{MAbsC} treated according to these guidelines demonstrated a treatment success rate of 80.5% at one year with a 10% relapse rate [46]. Another case series of 22 non-transplant patients on various treatment regimens reported less successful outcomes of only 36.4% improvement at one year [47]. However, these recommendations are for non-immunosuppressed host. These recommendations were published before the era of \textit{MAbsC} subspeciation and \textit{erm} gene phenotypic testing. One has to be cautious extrapolating the 2007 ATS/IDSA guidelines to immunosuppressed lung transplant recipients since optimal duration of treatment in this population is not known. Current evidence is limited to a few case series and retrospective studies in which treatment durations were often in the 6–9 months range but treatments of 12–24 months with microbiological response by 3 months or smear positive lung disease prolonged therapy or immunosuppression is not possible or if high disease burden exists, (disorgan rejection and allograft dysfunction. If reduction in immunosuppression is considered but this decision should be weighed against the potential risk of organ rejection and allograft dysfunction. If reduction in immunosuppression is not possible or if high disease burden exists, (dissemated disease or smear positive lung disease) prolonged therapy or lifelong suppression should be considered [6].

Aspergillus sp and \textit{Pseudomonas aeruginosa} infections occur frequently after treatment of \textit{MAbsC} disease with prolonged use of multidrug regimen. In one study 70% of patients treated for \textit{MAbsC} disease developed concurrent infections with \textit{Aspergillus, Pseudomonas, Clostridium difficile} or \textit{Stenotrophomonas} [5].

Treatment adherence is a very important factor in the success of the treatment regimen, and this has to be emphasized with appropriate patient education and close monitoring in a multidisciplinary environment. Complete microbiological clearance and/or cure from \textit{MAbsC} lung disease may not be achievable for some patients with the current antimicrobial agents, due to side effects and poor tolerability of medications. Long-term antimicrobials regimens designed with the goal of minimizing adverse effects of the medications while suppressing the infection can be considered [39]. Prolonged course of intravenous antibiotics with or followed by oral macrolide, clofazimine, and/or oral linezolid with inhaled amikacin can be used to suppress the infection. Periodic antibiotics can be considered for some to provide suppressive therapy, but long-term sputum conversion is rare and risk of developing additional drug resistance can increase [12]. In patients with \textit{MAbsC} empyema, in addition to surgical drainage of pleural space, prolonged intravenous multidrug regimen should be considered. This has to be followed by long term oral suppressive therapy [9].

Adjuvant surgical resection with optimal antimicrobial therapy is recommended and associated with the best chance of cure for immunocompetent patients with localized \textit{MAbsC} pulmonary disease [39]. However, a surgical treatment option can be challenging in lung transplant recipients with allograft dysfunction. In selected patients with localized disease and adequate lung function, surgical resection of the diseased portion of the lung following initial treatment with antimicrobial agents to decrease the disease burden can offer the best chance of cure [11,12].

Clofazimine may be a treatment option for macrolide resistant or intolerant regimen. Inhaled amikacin may have some benefits in patients with refractory \textit{MAbsC} disease although its role is still not very clear [36,49]. However, the combination of clofazimine with amikacin or clarithromycin is synergistic in vitro [50], therefore and at least in theory, the combined use of inhaled amikacin with clofazimine and a macrolide might enhance the microbiological control of the infection at the airway and cavitary disease levels. Bedaquiline also has been used as salvage therapy in few refractory MAA cases [51].

10.2. Treatment of skin, soft tissue and bone disease

Skin and soft tissue infection from \textit{MAbsC} in transplant recipients can be localized or disseminated, which is associated with considerable morbidity. Diagnosis is established by tissue biopsy, cultures and abscess drainage. In vitro susceptibility pattern would aid in the choice of the antimicrobials. In non-immunosuppressed host, multidrug regimen that includes a macrolide (for macrolide-susceptible strains), intravenous amikacin plus high-dose cefoxitin or imipenem is recommended by the ATS/IDSA guidelines. For severe disease, four months of combination therapy is recommended. In case of osteomyelitis, the therapy is extended to 6 months, and at least 2 months beyond the resolution of all clinical signs of infection [11,12,39]. However, the successfully cured immunosuppressed lung transplant patients received a combination of antimicrobials including amikacin for 6 months or longer [29]. Surgical drainage of abscesses and debridement of extensive disease should be performed. Surgical treatment has been recommended for cases with drug resistance and/or when drug therapy is challenging [39]. Surgical drainage of the localized cutaneous disease with parenteral antibiotics is also thought to be best treatment strategy for cutaneous infection [12]. Antimicrobial therapy alone for cutaneous infection might not be sufficient due to poor penetration [5]. Some of these infections require several or more surgical drainages [9]. Anti-biotic monotherapy might produce resistance hence combination therapy is generally recommended [5]. Chronic suppressive antimicrobial therapy might be required [7]. Topical amikacin cream has been used in skin and soft tissue infections, though the efficacy is not clear [9].

10.3. Toxicities of treatment

Treatment of \textit{MAbsC} in lung transplant recipients can be challenging due drug toxicities and to drug-to-drug interactions of antimicrobials with immunosuppressants and other medications used in these patients [34] (Tables 4 and 5). In fact, a transplant pharmacist assistance can be very helpful to carefully plan and dose antimicrobials and to very closely monitor antirejection drug and antimicrobials levels in these patients (Tables 5–7). Aminoglycosides can increase the nephrotoxicity when administered concomitantly with calcineurin inhibitors [5]. Use of systemic aminoglycosides may cause nephrotoxicity (15%), ototoxicity (37%) and vestibular toxicity (9%). Nephrotoxicity and vestibular toxicity are reversible in majority of the cases. The toxicity is not different when daily dosing was compared to three times weekly dosing. Older age, larger cumulative dose, longer duration of treatment are associated with risk of ototoxicity [52].

11. Survival and outcome

Development of \textit{MAbsC} disease after lung transplantation is associated with allograft dysfunction and higher mortality [8]. About 60% of lung transplant recipients with \textit{MAbsC} disease were cured with combination antimicrobial therapy, while 40% died. \textit{MAbsC} disease was the cause of death in some, but the greater proportion of the patients who died, succumbed to non-NTM infections, including sepsis from \textit{Aspergillus, Pseudomonas, and Clostridium difficile colitis} [5,8].

12. Conclusion

\textit{MAbsC} is a group of ubiquitous organisms that can cause significant morbidity, including chronic pulmonary infections and skin and soft
Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transpl 2011;30:790–8.

[9] Lobo LJ, Chang LC, Esther CR, Gilligan PH, Tulu Z, Noone PG. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 2013;27:523–9.

[10] Malouf MA, Gianville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999;160:1611–6.

[11] Griffith DE, Akamati T, Benden C, Catanzarite A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367–416.

[12] Colombo RE, Olivier KN. Diagnosis and treatment of infections caused by rapidly growing mycobacteria. Semin Respir Crit Care Med 2008;29:577–88.

[13] Zaidi S, Edlemir O, Heinle JS, McKenzie ED, Schecter MG, Kaplan SL, et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transplant Infect Dis 2009;11:245–9.

[14] Brown-Elliott BA, Wallace RJ. Clinical and taxonomic status of pathogenic non-pigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002;15:716–46.

[15] Garrison AP, Morris MJ, Dobblecki L, Smith L, Cleary TJ, Procop GW, et al. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transplant Infect Dis 2009;11:541–8.

[16] Philley JV, Griffith DE. Management of nontuberculous mycobacterium (NTM) lung disease. Semin Respir Crit Care Med 2013;34:135–42.

[17] Stout JE, Kow WJ, Yew WW. Update on pulmonary disease due to nontuberculous mycobacteria. Int J Tuberc Lung Dis 2016;21:433–9.

[18] Jovan K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009;180:896–902.

[19] Aitken ML, Limaye A, Pottinger P, Whimsey E, Goss CH, Tomelli MR, et al. Respiratory outcome of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012;185:231–8.

[20] Bryant JM, Gregorino DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, et al. Emergence and spread of a human-transmissible multidrug-resistant non-tuberculous mycobacterium. Science 2016;354:751–7.

[21] Morales P, Gil A, Santos M. Mycobacterium abscessus infection in transplant recipients. Transplant Proc 2010;42:3058–60.

[22] Longsworth SA, Vinnard C, Lee I, Sims KD, Barton TD, Blumberg EA. Risk factors for nontuberculous mycobacterium infections in solid organ transplant recipients: a case-control study. Transplant Proc 2014;46:76–82.

[23] Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011;52:565–71.

[24] Seymanyinski EP, Leung YM, Fowler CJ, Haney C, Hsu AP, Chen F, et al. Pulmonary nontuberculous mycobacterial infection: a multistem, multigenic disease. Am J Respir Crit Care Med 2015;192:618–28.

[25] Orme EM, Ordway DJ. Host response to nontuberculous mycobacterial infections of current clinical importance. Infect Immun. 2014;82:3516–22.

[26] Kim SY, Koy WJ, Kim YJ, Yeong BH, Park HY, Jean K. K. Importance of reciprocal balance of T cell immunity in Mycobacterium abscessus complex lung disease. PLoS One 2014;9:e99941.

[27] Steindor M, Nkwouano V, Mayatepek E, Mackenzie CR, Schramm D, Jacobsen MA. Rapid detection and immune characterization of Mycobacterium abscessus infection in cystic fibrosis patients. PLoS One 2015;10:e0197377.

[28] Taylor JL, Palmer SM, Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transpl 2015;22:985–8.

[29] Giljam M, Scherstén H, Silverborn M, Jönsson B, Ericsson Holling A. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros 2010;9:272–6.

[30] Qvist T, Persløl T, Thomsen VO, Skov M, Iversen M, Katzenstein TL. Nontuberculous mycobacterium infection is not a contraindication to lung transplantation in patients with cystic fibrosis: a retrospective analysis in a Danish patient population. Transpl Proc 2013;45:342–5.

[31] Akamati T, Philley JV, Griffith DE. Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials. Respir Excell 2014;108:417–25.

[32] Benwill JL, Wallace RJ. Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis 2014;27:506–10.

[33] Koh WJ, Jeon K, Kim BJ, Kook YH, Lee SH, et al. Clinical significance of treatment of Mycobacterium abscessus from Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:1855–60.

[34] Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med 2015;36:91–9.

[35] Snell GL, Westall GP, Parasekaya MA. Immunosuppression and allograft rejection following lung transplantation: evidence to date. Drugs 2013;73:1793–813.

[36] Jankovic Makek M, Pavliška G, Jakopovic M, Redzepi G, Zmak L, Vukic Dzag A, et al. Early onset of nontuberculous mycobacterial pulmonary disease contributes to the lethal outcome in lung transplant recipients: report of two cases and review of the literature. Transplant Proc 2014;46:2325–7.

[37] Fairhurst RM, Kubak BM, Shpiner RB, Levine MS, Pegues DA, Ardehali A. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant 2002;21:391–4.

[38] Longsworth SA, Blumberg EA, Barton TD, Vinnard C. Nontuberculous mycobacterial infections after solid organ transplantation: a survival analysis. Clin Microbiol Infect 2015;21:43–7.

[39] Kuperbauer SH, De Groote MA. The treatment of rapidly growing mycobacterial infections. Clin Chest Med 2015;36:67–78.
Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241–50.

Elkins MR, Robinson M, Rose BR, Harbour C, Mortarty CP, Marks GB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229–40.

Hart A, Sugumar K, Milan SJ, Fowler SJ, Crossingham I. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2014. CD002996.

Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012;67:810–8.

Choi GE, Shin SJ, Won CJ, Min KN, Oh T, Hahn MY, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012;186:917–25.

Wallace RJ, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2003;45:764–7.

Lyu J, Jang HJ, Song JW, Choi CM, Oh YM, Lee SD, et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med 2011;105:781–7.

Huang YC, Liu MF, Shen GH, Lin CF, Kao CC, Liu PY, Shi ZY. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. J Microbiol Immunol Infect 2010;43:401–6.

Shah SK, McAnally KJ, Sesane I, Lombard GA, LaPlace SG, Lick S, et al. Analysis of pulmonary non-tuberculous mycobacterial infections after lung transplantation. Transplant Int 2016;18:585–91.

Olivier KN, Shaw PA, Glaser TS, Bhattacharyya D, Fleshner M, Brewer CC, et al. Inhaled amikacin for treatment of refractory pulmonary non-tuberculous mycobacterial disease. Am J Respir Crit Care Med 2014;189:30–5.

Ferro BE, Meletiadis J, Wattenberg M, de Jong A, van Soolingen D, Mouton JW, van Ingen J. Clofazimine prevents the regrowth of mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin. Antimicrob Agents Chemother 2016;60:1097–105.

Philley JV, Wallace RJ, Benwill JL, Taskar V, Brown-Elliott BA, Thakkar F, et al. Preliminary results of bedaquiline as salvage therapy for patients with non-tuberculous mycobacterial lung disease. Chest 2015;147:499–506.

Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huiit GA, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38:1538–44.